



The percentage of men receiving appropriate management for testosterone deficiency syndrome (TDS) is small in comparison to prevalence estimates. Morales and colleagues describe their conclusions and defines an algorithm for appropriate TDS management. See page 269.

Le pourcentage d'hommes recevant une prise en charge appropriée pour un syndrome de carence en testostérone est faible en comparaison avec les taux de prévalence évalués. Le docteur Morales et ses collaborateurs présentent un rapport qui décrit leurs conclusions et propose un algorithme de prise en charge. Voir page 269.

All editorial matter in *CUAJ* represents the opinions of the authors and not necessarily those of the Canadian Urological Association. The CUA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CUAJ*.

Publications Mail Agreement no. 41614530. Return undeliverable Canadian copies to *CUAJ*, 1155 University Ave., Suite 1303, Montréal QC H3B 3A7; journal@cua.org.

Numéro de convention poste-publications 41614530. Retourner toutes copies canadiennes non livrées au *JAUC*, 1155 rue Université, Bureau 1303, Montréal QC H3B 3A7; journal@cua.org.

ISSN 1911-6470
e-ISSN 1920-1214

EDITORIAL

227 MRI and prostate cancer: the next frontier

L.H. Klotz

ÉDITORIAL

229 IRM et cancer de la prostate : vers de nouveaux horizons

L.H. Klotz

CUA NEWS

231 Next year – Montréal!

S. Herschorn

NOUVELLES DE L'AUC

231 À l'an prochain, Montréal !

S. Herschorn

PRACTICE GUIDELINE

232 High-intensity focused ultrasound for prostate cancer: a practice guideline

H. Lukka, T. Waldron, J. Chin, L. Mayhew, P. Warde, E. Winquist, G. Rodrigues, B. Shayegan, on behalf of the Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care

ORIGINAL RESEARCH

237 A cost-analysis comparison of laparoscopic radical prostatectomy versus open radical prostatectomy: the McMaster Institute of Urology experience

T.F. Al-Shaiji, N. Kanaroglou, A. Thoma, C. Prowse, V. Comondore, W. Orovan, K. Piercey, P. Whelan, L. Winter, E.D. Matsumoto

COMMENTARY

242 A cost analysis of radical prostatectomies: Will it ever be possible?

E.P. Estey

ORIGINAL RESEARCH

243 Wait times in prostate cancer diagnosis and radiation treatment

C. Stevens, S.J. Bondy, D.A. Loblaw

COMMENTARY

- 249 Dealing with wait times in prostate cancer**
B. Donnelly

ORIGINAL RESEARCH

- 250 Impact of body mass index on perioperative outcomes during the learning curve for robot-assisted radical prostatectomy**
V. Chalasani, C.H. Martinez, D. Lim, R. Al Bareeq, G.R. Wignall, L. Stitt, S.E. Pautler

COMMENTARY

- 255 Robotic surgery techniques for obese patients**
K.C. Zorn

ORIGINAL RESEARCH

- 257 Diagnostic accuracy of surface coil magnetic resonance imaging at 1.5 T for local staging of elevated risk prostate cancer**
B. Kim, R.H. Breau, D. Papadatos, D. Fergusson, S. Doucette, I. Cagiannos, C. Morash

ORIGINAL RESEARCH

- 263 Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline**
B.J.W. Miles, A.S. Fairey, M. Eliasziw, E.P. Estey, P. Venner, D. Finch, K. Trpkov, B.J. Eigel

COMMENTARY

- 268 Using clinical practice guidelines in our own backyard: treating our patients with bladder cancer**
P. Black

REVIEW

- 269 A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians**
A. Morales, A.J. Bella, S. Chun, J. Lee, P. Assimakopoulos, R. Bebb, I. Gottesman, P. Alarie, H. Dugré, S. Elliott

POINT/COUNTERPOINT

- 276 Medical versus surgical management for vesicoureteric reflux: the case for medical management**
A.J. Lorenzo

- 279 Rebuttal**
J. Franc-Guimond

- 280 Learning from history or the rationale for considering surgical correction of vesicoureteral reflux**
J. Riddell, J. Franc-Guimond

- 283 Rebuttal**
A.J. Lorenzo

201 IN MEMORIAM

RESOURCES

- 290 Career Opportunities**
284 Prescribing Information

ONLY ON CUAJ.CA

- Case reports
- Urology Meetings of Interest
- CME Calendar

ADVERTISERS' INDEX / INDEX DES ANNONCEURS

Amgen Canada
RANK Ligand, Inside Back Cover
AMS Canada Inc.
226
Pfizer Inc.
Sutent, Outside Back Cover, PI pages 284-8
Viagra, 224

sanofi-avenits
Eligard, Inside Front Cover, PI page 289
Solvay Pharma
AndroGel, 222